Corcept Therapeutics (NASDAQ: CORT) reported Q2 EPS of $0.29, $0.10 better than the analyst estimate of $0.19. Revenue for the quarter came in at $194.4 million versus the consensus estimate of $199.4 million.

GUIDANCE:

Corcept Therapeutics sees FY2025 revenue of $850-900 million, versus the consensus of $899 million.

For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.